Bevacizumab Treatment and Retinal Vessel Monitoring

Sponsor
Technische Universität Dresden
Study ID
NCT00740168
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Bevacizumab might influence the dynamic vessel function after being administered intravenously.

Key Dates

First listed
Aug 22, 2008
Start date
May 31, 2007
Status verified
Jan 2016
Primary completion
Dec 31, 2008
Completion
Apr 30, 2009

Study Design

Enrollment
20 participants (actual)

Arms

  • Arm: TG
    Bevacizumab treatment group with metastasized cancer

Primary Outcome Measure

Diameter of retinal vessels and dynamic vessel reaction [ Time Frame: Measurements before and after administration ]

Related Studies